Second Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Anticancer Res. 2012 Sep;32(9):4105-9.
We describe a case with rapid relapse after resection of a sunitinib-resistant gastrointestinal stromal tumor (GIST). Liver metastases and foci of left retroperitoneal recurrence developed during adjuvant imatinib treatment. The tumors did not shrink after sunitinib treatment, and hepatectomy and retroperitoneal tumorectomy were performed. Histological examination showed a Ki67 labeling index of over 50% in viable tumor cells. Genomic analysis revealed mutations in exons 11 and 13 of the c-KIT gene. Computed-tomographic scan revealed retroperitoneal recurrence at the surgical site five weeks post-operatively. In this case, high proliferative activity of the recurrent foci was associated with resistance to sunitinib and rapid recurrence during the perioperative withdrawal of sunitinib. It is important to consider the possibility of an exon 13 mutation with an aggressive phenotype when treating sunitinib-resistant GISTs. Surgical intervention for sunitinib-resistant GISTs should be carefully considered if R0 resection is not possible.
我们描述了一例舒尼替尼耐药胃肠道间质瘤(GIST)切除后快速复发的病例。在辅助伊马替尼治疗期间,发生了肝转移和左腹膜后复发灶。舒尼替尼治疗后肿瘤未缩小,遂行肝切除术和腹膜后肿瘤切除术。组织学检查显示存活肿瘤细胞的 Ki67 标记指数超过 50%。基因组分析显示 c-KIT 基因外显子 11 和 13 发生突变。术后五周计算机断层扫描显示手术部位腹膜后复发。在这种情况下,复发病灶的高增殖活性与对舒尼替尼的耐药性和舒尼替尼停药期间的快速复发有关。在治疗舒尼替尼耐药性 GIST 时,需要考虑具有侵袭性表型的外显子 13 突变的可能性。如果不能达到 R0 切除,应慎重考虑对舒尼替尼耐药性 GIST 进行手术干预。